Source comparison
Thymosin Alpha-1 vs VIP: Research Application Comparison
Primary Mechanism TLR-9 agonist → T-cell activation, IL-2/IFN-γ upregulation VPAC1/VPAC2 agonist → cAMP increase, NF-κB inhibition Thymosin Alpha-1 enhances adaptive immunity; VIP suppresses inflammation Target Tissue Thymus, lymph nodes, dendritic cells Brain
This comparison does not assign a generated winner or score.
- Primary Mechanism
- TLR-9 agonist → T-cell activation, IL-2/IFN-γ upregulation
- VPAC1/VPAC2 agonist → cAMP increase, NF-κB inhibition
- Thymosin Alpha-1 enhances adaptive immunity; VIP suppresses inflammation
- Target Tissue
- Thymus, lymph nodes, dendritic cells
- Brain, gut, smooth muscle, immune cells
- Thymosin Alpha-1 for immune modulation; VIP for neuroprotection and GI function
- Half-Life
- ~2 hours (acetylated, serum-stable)
- <2 minutes (rapid DPP-IV degradation)
- VIP requires depot or intranasal delivery; Thymosin Alpha-1 tolerates subcutaneous injection
- Typical Research Dose
- 1.6mg subcutaneous, twice weekly
- 25–50μg intranasal or 10–20μg/kg IV
- Dosing schedules reflect half-life differences
- Observable Effect
- Increased CD4+/CD8+ T-cell counts, enhanced NK cell activity
- Reduced TNF-α/IL-6, improved cerebral perfusion, bronchodilation
- Effects measured via flow cytometry for Thymosin Alpha-1, cytokine panels for VIP
- Clinical Trial Evidence
- Phase III data in hepatitis B, sepsis (1.6mg twice weekly)
- Phase II data in COPD, autism (intranasal 25μg daily)
- Thymosin Alpha-1 stronger immune data; VIP stronger neuroinflammation data
- This table shows that the two peptides occupy different biological niches. Thymosin Alpha-1 is a tool for immune system restoration. Particularly in scenarios where T-cell function is suppressed. VIP is a neuroinflammatory and vascular modulator. Used when cytokine storms, microglial overactivation, or impaired cerebral perfusion are the primary concerns.